An Extension of Protocol PRO 140_CD01 Study
Trial details
- Registry ID
- NCT02355184
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as PRO 140
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Extension of Protocol PRO 140_CD01 StudyNCT02355184 | CytoDyn, Inc. | Phase 2 | Terminated | 2022-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |